How many clinical trials are studying Melphalan?

5 recruiting trials in our tracked data involve Melphalan.

What conditions is Melphalan being studied for?

In our tracked recruiting trials, Melphalan is being studied in trials for Crohn's Disease, Adenocarcinoma of the Breast, BRCA1 Mutation.

Melphalan: clinical trials recruiting now

Q: Is Melphalan FDA-approved?

Yes. According to the FDA drug label available through openFDA, Melphalan is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Melphalan appears in the FDA drug-label database. Marketed as EVOMELA.
Boxed warning: The FDA label for Melphalan carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. ( 1.1 ) 1.1 Multiple Myeloma-Conditioning Treatment Evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.

FDA label via openFDA

Phase breakdown

Phase 1 4 Phase 2 4

Conditions being studied

Condition	Trials
Crohn's Disease	2
Adenocarcinoma of the Breast	1
BRCA1 Mutation	1
BRCA2 Mutation	1
Breast Cancer Metastatic	1
Breast Cancer Stage IV	1
CKD Stage 4	1
Congenital Bone Marrow Failure Syndromes	1
Cystinosis	1
FSGS	1
HER2 Negative Breast Carcinoma	1
HER2-negative Breast Cancer	1
Hereditary Anemias	1
Inflammatory Conditions	1
Inherited Metabolic Disorders (IMD)	1

Recruiting trials involving Melphalan

Autologous Stem Cell Transplantation for Crohn's Disease
NCT00692939 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 60 Years · Sex: All (male and female) · 2 locations
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
NCT05508009 · Phase: Phase 1, Phase 2 · Ages: 1 Year to 30 Years · Sex: All (male and female) · 1 location
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
NCT07281924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415 · Phase: Phase 2 · Ages: 2 Months to 55 Years · Sex: All (male and female) · 2 locations
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT04150042 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

Is Melphalan FDA-approved?

Yes, marketed as EVOMELA. Its FDA label carries a boxed warning.

How many recruiting trials involve Melphalan?

5 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.